Pharmacy Program Updates: Prior Authorization Changes Effective June 15, 2026
Act
by Jul 1, 2026
Effective date
Jul 1, 2026
Identified
Jun 16, 2026
Summary
Blue Cross Blue Shield of Illinois is updating prior authorization criteria for multiple pharmacy programs effective July 1, 2026, including new programs for Aqvesme and Voyxact, and criteria updates for medications treating conditions like migraine, amyloidosis, and immunomodulators. These changes affect members with prescription drug benefits administered by Prime Therapeutics across various plan types.
Get alerts when payers change rules like this one
We check BCBS Illinois and other payers every day and email you when a change matches your specialty and state.
01Clinical staff must review updated prior authorization criteria for affected pharmacy programs including Acute Migraine, Aqvesme, ATTR Amyloidosis, Biologic Immunomodulators, Constipation Agents, Continuous Glucose Monitor, IL-4 Inhibitors, Otezla, Tezspire, and Vijoice medications.
02Update prescribing workflows to ensure compliance with new PA requirements.
03Note that some programs (Interstitial Lung Disease and TPO-RA) have earlier effective date of April 15, 2026, and Voyxact becomes effective August 1, 2026.
If missed: Failure to obtain required prior authorization may result in coverage denials.
Original notice
Pharmacy Program Updates: Prior Authorization Changes Effective June 15, 2026
bcbsil.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.